Retrograde capabilities of adeno-associated virus vectors in the central nervous system
Authors:
- Magdalena M. SurdykaMSMagdalena M. Surdyka
- Maciej FigielMFMaciej Figiel
Open Access
- 22 December 2021
- journal article
- review article
- Published by Termedia Sp. z.o.o. in BioTechnologia
- Vol. 102 (4) , 473-478
Abstract
Adeno-associated virus (AAV) vectors delivered at the axonal terminals can be retrogradely transported toward neuronal cell bodies throughout the axons. This retrograde phenomenon can serve as a powerful tool for experiments and gene therapy using AAVs. The advantages of using AAV vectors delivered retrogradely are greater cellular specificity, high transduction efficiency, increased safety, and absence of cytotoxicity. The numerous axonal projections in the nervous system provide a neuronal network for the convenient and widespread distribution of viral vectors between adjacent brain structures and over long distances. The retrograde efficiency of AAVs in the neurons of the central nervous system (CNS) depends on AAV serotype, the region of injection, and the type of neurons. In this review, we describe AAV serotypes and their retrograde transport properties after injection and discuss brain structures or types of cells that are targeted for retrograde transport. In particular, AAV serotypes 2, 5, 8, 9, rh10, and PHP.eB are extensively reviewed as they demonstrate retrograde transport potential suitable for use in gene therapy applications.Keywords
This publication has 30 references indexed in Scilit:
- Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse BrainPLOS ONE, 2013
- AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALSNeurobiology of Disease, 2012
- Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9Neuroscience, 2011
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADCMolecular Therapy, 2010
- AAV8, 9, Rh10, Rh43 Vector Gene Transfer in the Rat Brain: Effects of Serotype, Promoter and Purification MethodMolecular Therapy, 2008
- A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic DiseaseJournal of Neuroscience, 2007
- Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse BrainHuman Gene Therapy, 2007
- AAV Vector-Mediated Correction of Brain Pathology in a Mouse Model of Niemann–Pick A DiseaseMolecular Therapy, 2005
- Targeted Retrograde Gene Delivery for Neuronal ProtectionMolecular Therapy, 2002